Both PSR and EGAN acknowledge the importance of involving patient groups at an earl
...
Read more »
The development of drug and biological products intended to treat rare diseases is one of the fastest growing areas of clinical research and one of the most challenging, particularly for drug developers entering the orphan field for the first time. Orphan drug development presents fundamentally different regulatory and operational challenges than traditional drug development and involves interest of different stakeholders, including individual patients, rare disease patient groups, key opinion leaders, government bodies and payors.
PSR is the leading expert in orphan drug development. We assist our clients to design and execute successful clinical development strategies for orphan indications. We are specialized in complex clinical development programs requiring innovative regulatory and clinical approaches.
03-02-2012 - PSR is part of two stage-2 FP7 applicationsPSR joined a total of two FP7 consortia for stage 2 of the 2012 FP7-HEALTH-20120-INNOVATION-1 call: preclinical an ... |
07-12-2011 - PSR to lead orphan drug MasterclassDr Anthony Hall, PSR’s Chief Medical Officer, will be leading an orphan drug Masterclass on 7th December 2011. ... |
01-02-2011 - PSR patients group EGAN sign intent to collaborateBoth PSR and EGAN acknowledge the importance of involving patient groups at an earl ... |
05-06-2010 - PSR launches new service: OrphanIQPRESS RELEASE Hoofddorp, The Netherlands, July 5, 2010 / – PSR announced today ... |